Stock Price Quote

WANBURY LTD.

NSE : WANBURYBSE : 524212ISIN CODE : INE107F01022Industry : Pharmaceuticals & DrugsHouse : Private
BSE292.302.05 (+0.71 %)
PREV CLOSE ( ) 290.25
OPEN PRICE ( ) 288.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4799
TODAY'S LOW / HIGH ( )281.00 296.00
52 WK LOW / HIGH ( )132.7 330
NSE291.811.93 (+0.67 %)
PREV CLOSE( ) 289.88
OPEN PRICE ( ) 280.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 291.81 (309)
VOLUME 40434
TODAY'S LOW / HIGH( ) 278.55 298.00
52 WK LOW / HIGH ( )131.2 329.7
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1988
Management Info
- Chairman - Managing Director
Registered Office

Address B S E L Tech Park,B - Wing, 10th Floor, Sector 30 A,Opp. Vashi Railway Station, Vashi,
Navi Mumbai,
Maharashtra-400703

Phone 022-67942222 / 71963222

Email info@wanbury.com

Website www.wanbury.com

Registrars Details
Purva Shareregistry (India) Pvt Ltd
Gala No 9,Shiv Shakti, Industrial Estate,Sitaram Mill Comp.,J R Boricha Marg, Lower Parel [E],Mumbai
Listing : BSE, NSE, Luxembourg

NEWS

20May Wanbury gets GMP certificate for Patal
Wanbury’s Patalganga manufacturing site has successfully received Good M..
23Apr Wanbury informs about updates
Pursuant to Regulation 30 (6) of SEBI (Listing Obligations and Disclosur..
24Mar Wanbury to launch two new products
Wanbury is all set to launch two new products, for formulation (Branded..
06Mar Wanbury informs about press release
Pursuant to Regulation 30 of SEBI Listing Regulations, Wanbury has infor..
03Jan Wanbury completes Brazilian Health Aut
Wanbury has successfully completed the Brazilian Health Authority (ANVIS..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit202.57305.299999999999
Gross Profit 190.55 295.509999999999
Operating Profit 314.71798.129999999999
Net Sales 17205995.14

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Glaxosmithkline Phar (BSE)
peergroup  2984.45 (7.07%)
M.Cap ( in Cr)50770.99
Caplin Point Lab (BSE)
peergroup  2250.95 (5.75%)
M.Cap ( in Cr)16973.41
Alkem Laboratories (BSE)
peergroup  5379.00 (2.25%)
M.Cap ( in Cr)64290.10
Divi's Lab (BSE)
peergroup  6558.00 (1.66%)
M.Cap ( in Cr)174146.06
Astrazeneca Pharma I (BSE)
peergroup  7999.50 (0.99%)
M.Cap ( in Cr)20067.88

Shareholding Pattern

NON-INSTITUTION 58.68%
PROMOTERS 39.76%
FI/BANKS/INSURANCE 0%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%
FII 0%

About Wanbury Ltd.

Wanbury Ltd. was incorporated in the year 1988. Its today's share price is 292.3. Its current market capitalisation stands at Rs 969.84 Cr. In the latest quarter, company has reported Gross Sales of Rs. 5808.22 Cr and Total Income of Rs.5786.4 Cr. The company's management includes Manojkumar Khubchand Gursahani, Pallavur Sankar Dass Vaidyanathan, Jitendra J Gandhi, Mridul Mehta, Mohan Kumar Rayana, Anupama Vaidya, K Chandran.

It is listed on the BSE with a BSE Code of 524212 , NSE with an NSE Symbol of WANBURY and ISIN of INE107F01022. It's Registered office is at B S E L Tech Park,B - Wing, 10th Floor, Sector 30 A,Opp. Vashi Railway Station, VashiNavi Mumbai-400703, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Kapoor & Parekh Associates, V Parekh & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.